Privately-owned GenKyoTex SA has raised 14.5 million Euro to bring a compound for diabetic nephropathy into the clinic and advance other programmes. The Series C round was led by Edmond de Rothschild Investment Partners of Paris, France. ---Subscribe to MedNous to access this article--- Company News
